Canadian Meds |
Policy | Legal
Terms | Meds Index
Acomplia, aka. Rimonabant is a well-known anti-obesity drug. It was allowed and opened to general market sale in the European Union in June 2006. Acomplia is not yet approved by the United States, where the drug holds the name Zimulti.
The drug is currently the first in a new class of therapeutic called cannabinoids-1-receptor blockers (CB1) for the treatment of obesity and the other associated Basal Metabolic Rate (BMR) malfunctioning.
Acomplia is used to supplement the diet and exercise to help reduce obesity and overweight in patients with Type II diabetes and abnormal fat in the blood. Off and on, the drug has the potential to substantially reduce the chances of cardio-vascular diseases.
Rimonabant has been effective in supporting some smokers to quit smoking. Currently studies have been conducted in order to determine the possible value of rimonabant in smoking cessation therapy. The STRATUS (Studies with Rimonabant and Tobacco Use) Program has involved more than 6,000 subjects and has designed to explore two smoking related therapies:
Use Rimonabant directly to help quit smoking.
Use Rimonabant to help prevent weight gain in smokers.
Primary outcome actually suggest that rimonabant is effective for both the uses.
Rimonabant has effects to reduce the resumption of cocaine seeking responses and it has been found that two of the three most common things that trigger the response on human are relapsed; also it may reduce ethanol and opiate seeking activities.
Memory: Rimonabant has been hypothesized to improve short term memory and studies done on animals have shown significant improvement in performance.
Side effects: The real deal about Acomplia Rimanobant is that it makes you feel that you are following a normal diet but the fact is, it accelerates the procedure by increasing your metabolism thus making you burn fat and will also make you think that you are eating normally.
Some main side effects of acomplia Rimanopant are headaches, or vomiting, or insomnia however as you start using it regularly these side effects disappear.
However studies conducted shortly after it was introduced in market revealed that the side effects occur strongly and more commonly than shown by the manufacturer in their clinical studies, reports of severe depression was found out to be more frequent. This was the result because the drug affects the central nervous system, an area of human structure so multifaceted that the effects of a drug are exceedingly difficult to forecast or foresee.
Since the drug has the contradictory effects of cannabinoid receptor agonists such as tetrahydrocannabinol which is one of the substances found in marijuana, is very neuroprotective against excitotoxicity.
Based on this theory, Rimonabant promotes and develops neurodegenerative diseases of the central nervous system such as Multiple sclerosis, Alzheimer's disease, Amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease in persons who are susceptible.
Hence, considering this fact, consuming Rimonabant by any patients who has any neurological condition should avoid taking Rimonabant, given the neuroprotective role of the endocannabinoid system in many experimental paradigms of neurological disease.
Consult your physician before you begin intake of the medicine. The physician will recommend you appropriate dose of the drug, only after diagnosing the situation.
© 2003-2017 Rx Meds Canada . All Rights Reserved